Preventing graft-versus-host disease in kids after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy, Infections, Skin clinical trials.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 6 months to 26 years at the time consent is signed
- Have a qualifying blood cancer with low blast counts (exact cutoff depends on diagnosis) or certain MDS after induction chemotherapy
- Plan to receive a donor stem cell transplant from a donor matched at 8/8 genetic markers (HLA-A, -B, -C, -DRB1) and use bone marrow (BM) or collected stem cells (PBSC), not cord blood
- Have heart and lung function tests that meet limits (heart pumping strength and lung test results or oxygen level on room air)
- Have blood chemistry and kidney/liver tests within allowed ranges (or be judged okay by specialists if slightly high)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Hear when a new Acute Biphenotypic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.